Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2011. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,650,000 Ordinary shares of 25 pence each.
- Purchase Date: June 24, 2011.
- Price Range: Highest price paid was 1,300.5 pence per share; lowest price paid was 1,285 pence per share.
- Treasury Shares Held: 499,174,284 shares (representing 8.85% of total issued share capital and 9.71% of total voting rights).
- Shares in Issue: 5,140,741,295 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 1,650,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 499,174,284.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under the Financial Services Authority's Disclosure and Transparency Rules regarding the share buyback execution.
Investor Verification Checklist
- Verify the total number of shares in issue (5,140,741,295) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.71%).
- Note that the repurchased shares were cancelled, permanently reducing the company's share capital.